Effects of Endotoxin in Normal Human Volunteers
Launched by NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER (CC) · Nov 3, 1999
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
Endotoxin is a unique molecule because it represents an important probe for investigating the humoral and cellular basis of septic shock. Endotoxin administration to humans provides an opportunity to evaluate the earliest responses that are activated after exposure to an important bacterial component. Many alterations in organ function and circulating mediators can be evaluated in this model. These changes are qualitatively similar to changes that occur during sepsis and septic shock. The applications of new technologies to this model are useful adjuncts to define mechanisms of acute inflam...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • 1. 18 to 45 years of age, either male or female
- • 2. Employees or non-employees are eligible
- 3. Normal screening examination:
- • 1. history and physical examination, nonsmoker, no concurrent medications including aspirin or nonsteroidal anti-inflammatory drugs, no active medical problems;
- • 2. complete blood count with differential and platelet counts;
- • 3. serum chemistries including creatinine, blood urea nitrogen, glucose, liver enzymes and function tests, electrolytes, prothrombin time, partial thromboplastin time;
- • 4. urinalysis;
- • 5. female subjects must have negative urine pregnancy test within one week of participation;
- • 6. electrocardiogram;
- • 7. chest radiograph.
- • 4. If age is 40 to 45 years, normal submaximal stress test to screen for asymptomatic coronary artery disease.
- EXCLUSION CRITERIA:
- • Pregnancy.
- • Lactation.
- • History of recent clinically significant asthma.
- • Subjects who have an allergy to both sulfa- and penicillin-based drugs will not be eligible for the endotoxin instillation portion of the study.
About National Institutes Of Health Clinical Center (Cc)
The National Institutes of Health Clinical Center (CC) is the nation's largest hospital dedicated exclusively to clinical research, serving as a pivotal facility for advancing medical knowledge and innovative therapies. Located in Bethesda, Maryland, the Clinical Center provides a unique environment where patients have access to cutting-edge treatments and participate in groundbreaking clinical trials across a wide range of diseases. As a leader in translational research, the CC integrates patient care with scientific investigation, fostering collaboration among researchers, clinicians, and patients to accelerate the development of new interventions and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Anthony F Suffredini, M.D.
Principal Investigator
National Institutes of Health Clinical Center (CC)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials